deltatrials
Completed PHASE1 NCT00038051

Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

Phase I Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

Sponsor: M.D. Anderson Cancer Center

Conditions Acute Myeloid Leukemia Anemia, Refractory, With Excess of Blasts Chronic Myelomonocytic Leukemia Myeloproliferative Disorders
Interventions Hum-195/rGel
Updated 6 times since 2017 Last updated: Apr 1, 2013 Started: May 31, 1999 Primary completion: Feb 28, 2013 Completion: Feb 28, 2013

Listed as NCT00038051, this PHASE1 trial focuses on Acute Myeloid Leukemia and Anemia, Refractory, With Excess of Blasts and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 6 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

May 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States